BVA has expressed concern following the announcement by the Veterinary Medicines Directorate (VMD) regarding the reclassification of Zolvix, an anthelmintic for sheep, from POM-V to a POM-VPS.
BVA President Gudrun Ravetz said:
"We know that resistance to anthelmintics is increasing in grazing animals and needs to be addressed if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites. The reclassification of Zolvix from POM-V to POM-VPS is in direct opposition to the trend in Europe, where we are seeing increased control over dispensing of anthelmintics in species where resistance is a serious threat to animal welfare and profitable production; we're extremely concerned that we might start seeing resistance develop in group 4 as a result.
“BVA believes that prescribing of anthelmintics requires a level of control best provided by a veterinary surgeon who has the animals under his/her care, and is based on a sound clinical diagnosis, in order to protect animal welfare and safeguard the efficacy of these products for the future."
Further information on BVA's policy on anthelmintics can be found here: www.bva.co.uk/news-campaigns-and-policy/policy/medicines/anthelmintics.